Investigator

Anita Sveen

Group leader of Computational Oncology · Oslo University Hospital, Institute of Cancer Research

ASAnita Sveen
Papers(1)
Evolutionary mode and…
Collaborators(3)
Kjetil TaskénOla MyklebostRolf I. Skotheim
Institutions(4)
Oslo University Hospi…University of OsloUniversity of BergenUniversity of Oslo

Papers

Evolutionary mode and timing of dissemination of high-grade serous carcinomas

Dissemination within the peritoneal cavity is a main determinant of poor patient outcomes from high-grade serous carcinomas (HGSCs). The dissemination process is poorly understood from a cancer evolutionary perspective. We reconstructed the evolutionary trajectories across a median of 5 tumor sites and regions from each of 23 patients based on deep whole-exome sequencing. Polyclonal cancer origin was detected in 1 patient. Ovarian tumors had more complex subclonal architectures than other intraperitoneal tumors in each patient, which indicated that tumors developed earlier in the ovaries. Three common modes of dissemination were identified, including monoclonal or polyclonal dissemination of monophyletic (linear) or polyphyletic (branched) subclones. Mutation profiles of initial or disseminated clones varied greatly among cancers, but recurrent mutations were found in 7 cancer-critical genes, including TP53, BRCA1, BRCA2, and DNMT3A, and in the PI3K/AKT1 pathway. Disseminated clones developed late in the evolutionary trajectory models of most cancers, in particular in cancers with DNA damage repair deficiency. Polyclonal dissemination was predicted to occur predominantly as a single and rapid wave, but chemotherapy exposure was associated with higher genomic diversity of disseminated clones. In conclusion, we described three common evolutionary dissemination modes across HGSCs and proposed factors associated with dissemination diversity.

51Works
1Papers
3Collaborators

Positions

2025–

Group leader of Computational Oncology

Oslo University Hospital · Institute of Cancer Research

2018–

Associate Professor

University of Oslo · Faculty of Medicine, Inst. Clinical Medicine

2007–

Senior researcher & Project group leader

Oslo University Hospital · Inst. Cancer Research, Dept. Molecular Oncology